First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

In vivo expansion of haploidentical natural killer (NK) cell infusions with interleukin-2 (IL-2) can induce remission of refractory acute myeloid leukemia, but efficacy may be hampered by concurrent stimulation of host regulatory T cells. To overcome this limitation, we substituted the NK homeostati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Cooley, Sarah, He, Fiona, Bachanova, Veronika, Vercellotti, Gregory M., DeFor, Todd E., Curtsinger, Julie M., Robertson, Paul, Grzywacz, Bartosz, Conlon, Kevin C., Waldmann, Thomas A., McKenna, David H., Blazar, Bruce R., Weisdorf, Daniel J., Miller, Jeffrey S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6616260/
https://ncbi.nlm.nih.gov/pubmed/31266741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018028332
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados